Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited (RDY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
rdy · pe ratio · data through Mar 31, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Dr. Reddy's Laboratories Limited (RDY) measures how much investors pay for each dollar of the company's trailing earnings. RDY's current PE ratio of 24.82x is calculated by dividing its stock price of $13.23 by its TTM earnings per share of $51.40. +17.0% elevated vs 5Y avg 21.2x
Source: FMP · /ratios-ttm · /analyst-estimates · 2026-03-31
PE Ratio History
2007 – 2026 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 19 fiscal years · Front-end computedMinQ1 · 25%24.9x
MedianQ3 · 75%3220.8x
Max
At 24.82x, RDY's current P/E is within its average historical range over the past 19 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Dr. Reddy's Laboratories LimitedYou RDY | $11.0B | 24.82x | -0.8% | $51.40 |
 BioMarin Pharmaceutical Inc. BMRN | $10.9B | 32.67x | +30.5% | $1.82 |
 Encompass Health Corporation EHC | $10.0B | 18.84x | -24.7% | $5.63 |
 Elanco Animal Health Incorporated ELAN | $11.8B | N/A | — | -$0.47 |
 The Ensign Group, Inc. ENSG | $9.1B | 29.02x | +16.0% | $6.00 |
 Exelixis, Inc. EXEL | $13.0B | 15.12x | -39.6% | $2.88 |
 Neurocrine Biosciences, Inc. NBIX | $16.4B | 29.49x | +17.8% | $4.81 |
Industry Average 5 peers with valid PE | — | 25.03x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2026-03-31Latest FY2026 | 23.89x | $54.16 | +43.7% | |
2025-03-31 FY2025 | 16.63x | $67.85 | -9.9% | |
2024-03-31 FY2024 | 18.45x | $66.80 | +7.0% | |
2023-03-31 FY2023 | 17.24x | $54.29 | -42.3% | |
2022-03-31 FY2022 | 29.85x | $28.42 | -99.1% | |
2021-03-31 FY2021 | 3220.81x | $0.28 | +12247.4% | |
2020-03-31 FY2020 | 26.08x | $23.53 | +4.9% | |
2019-03-31 FY2019 | 24.86x | $22.66 | -30.3% | |
2018-03-31 FY2018 | 35.68x | $11.83 | -1.0% | |
2017-03-31 FY2017 | 36.05x | $14.45 | +41.0% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Dr. Reddy's Laboratories Limited (RDY) measures how much investors pay for each dollar of the company's trailing earnings. RDY's current PE ratio of 24.82x is calculated by dividing its stock price of $13.23 by its TTM earnings per share of $51.40.
Frequently asked questions
RDY pe ratio · 6 questionsRDY's current PE ratio is 24.82x as of 2026-06-08, based on a stock price of $13.23 and TTM EPS of $51.40. Data sourced from Financial Modeling Prep via RDY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Dr. Reddy's Laboratories Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08